Pozen has reported positive results from Phase 1 study of PA8140, a combination of aspirin (81mg) and omeprazole (40mg).

The study demonstrated comparable bioavailability relative to enteric-coated (EC) aspirin (81mg), the reference listed product for gastric ulcers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study also found that, considering highly variable drug criteria, PA8140 is bioequivalent to EC aspirin (81mg).

Pozen chief medical officer Dr. John Fort said the adjustments made in the trial design on the basis of earlier studies with PA formulations and discussions, improved the ability to capture and measure blood levels of aspirin.

"We believe that these results will satisfy the requirements set forth by the Food and Drug Administation (FDA) for establishing a therapeutic bridge to EC aspirin (81 mg) for this lower strength of PA tablets," Dr. Fort added.

See Also:

PA is a portfolio of integrated aspirin therapies that are targeted toward mitigating GI ulcers and other GI complications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The portfolio includes PA32540, which contains 325mg of aspirin, and PA8140with 81mg of aspirin.

All the trials will be included in the PA32540/PA8140 new drug application (NDA).

The company also completed manufacturing PA8140 tablet batches that met all predetermined specifications, essential for primary NDA stability programme.

Pozen chief commercial officer and executive vice president Liz Cermak said: "If approved, the availability of both 81 mg and 325 mg doses of PA will allow us to provide physicians an option for virtually all of their secondary prevention cardiovascular patients who are at risk for gastric ulcers, dramatically improving the commercial opportunity for PA."